3. Results
death, headaches, ±, hemophilia, gastrointestinal discomfort
CORONAVIRUS DISEASE 2019, HEMOPHILIA, ADVERSE EVENT, ORF
A total of 346 patients infected with SARS-CoV-2 Omicron variant were recruited, with 15 patients participated in other clinical studies, 10 patients refused and 1 patient with hemophilia. Finally, a total of 320 patients were included, with mean age of 29.10 ± 7.34 years old. There were 200 patients receiving Paxlovid. During the treatment, 3 patients in the Paxlovid group refused to take the medication due to its taste, and 2 patients withdrew due to transfer to another hospital. A total of 315 patients completed the treatment (Fig. Baseline characteristic of participants on admission.Real-time PCR Ct value.Time from onset to enrolment in patients, including the time of initial symptoms or the first positive nucleic acid.According to WHO criteria.BMI = body mass index, CT. N = Ct values of positive nucleic acid N gene, CT. ORF = Ct values of positive nucleic acid ORF gene, Paxlovid = Nirmatrelvir plus ritonavir.Follow chart.Compared to patients with standard treatment, patients with Paxlovid had a significantly shorter nucleic acid shedding time (3.26 ± 1.80 vs 7.75 ± 3.68, Outcomes for infected patients with Omicron variants.Paxlovid: Nirmatrelvir plus ritonavir.The major clinical outcomes of Paxlovid treatment in adult patients. Data are presented as means and 95% confidence intervals. (A) D until negative swab test. (B) Nucleic acid shedding time. (C) D of first symptoms resolution. (D) Hospital stay.Line chart for the negative rate of nucleic acid.During the follow-up period, a total of 62 patients (24.72%) had post-COVID-19 condition within 3 months after discharge. There was significant difference in post-COVID-19 condition [32 (18.60%) vs 30 (31.57%), Outcomes of follow-up study.BMI = body mass index, COVID-19 = coronavirus disease 2019, Paxlovid = Nirmatrelvir plus ritonavir.Multivariable analysis.CI = confidence interval, COVID-19 = coronavirus disease 2019, HR = hazards ratio, OR = odds ratio, Paxlovid = Nirmatrelvir plus ritonavir.Adjusted model: sex, age, height, weight, CT.N, CT.ORF, d from onset to admission.After analyzing the nucleic acid results of patients with Paxlovid, some patients had 2 consecutive negative nucleic acid results or N gene and ORF gene Ct values ≥ 35 (with at least 24 hours between samplings), but later they tested positive again in the subsequent nucleic acid test (Fig. Heat map of the Ct values of ORF and N genes in Paxlovid group patients’ nucleic acid testing within 8 d.No serious adverse event or death occurred in the 2 groups during the treatment progress. In the Paxlovid group, 12 patients (6%) experienced a bitter taste in their mouth, including 3 patients (1.5%) who refused to continue taking the medication and dropped out of the study. Additionally, 3 patients (1.5%) experienced gastrointestinal discomfort, and 2 patients (1%) experienced headaches. All these symptoms disappeared after the medication course was completed.